Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in preclinical melanoma models

被引：0

作者：

Quagliariello, Vincenzo

Cortellino, Salvatore

Delfanti, Gloria

Di Mauro, Annabella

Tatangelo, Fabiana

Spagnolo, Vanessa

Visco, Euplio

Casorati, Giulia

Chiodoni, Claudia

Della Bona, Paolo

Blazevits, Olga

Ascierto, Paolo Antonio

Maurea, Nicola

Longo, Valter

机构：

[1] IRCCS Fdn G Pascale, Naples, Italy

[2] IRCCS CROB, Rionero In Vulture, Italy

[3] IRCCS S Raffaele Sci Inst, Milan, Italy

[4] Ist Nazl Tumori IRCCS Fdn G Pascale, Pathol Unit, Naples, Italy

[5] Natl Canc Inst Naples, Naples, Italy

[6] IFOM, Milan, Italy

[7] San Raffaele Inst, Milan, Italy

[8] Fdn IRCCS Isttuto Nazl Tumori, Milan, Italy

[9] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[10] Ist Nazl Studio & Cura Tumori Fdn G Pascale IRCCS, Div Cardiol, Naples, Italy

[11] IFOM FIRC Inst Mol Oncol, Milan, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

12029

引用

页数：1

共 50 条

[21] Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Su, Xin
Li, Jian
Xu, Xiao
Ye, Youbao
Wang, Cailiu
Pang, Guanglong
Liu, Wenxiu
Liu, Ang
Zhao, Changchun
Hao, Xiangyong
JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
[22] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Afzal, Muhammad Zubair
Mabaera, Rodwell
Shirai, Keisuke
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[23] Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review
Papouin, Barbara
Mussini, Charlotte
De Martin, Eleonora
Guettier, Catherine
ANNALES DE PATHOLOGIE, 2018, 38 (06) : 338 - 351
[24] Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Seidel, Judith A.
Otsuka, Atsushi
Kabashima, Kenji
FRONTIERS IN ONCOLOGY, 2018, 8
[25] Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, Spencer C.
Levine, Jacob H.
Pe'er, Dana
Allison, James P.
CANCER RESEARCH, 2017, 77
[26] Tumor eradication in a murine model of glioma with vaccination and anti-CTLA-4 but not anti-PD-1
Field, Cameron S.
Hunn, Martin K.
Ferguson, Peter M.
Yagita, Hideo
Hermans, Ian F.
Ancelet, Lindsay R.
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
[27] Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, Spencer
Levine, Jacob
Cogdill, Alexandria
Zhao, Yang
Anang, Nana-Ama
Andrews, Miles
Sharma, Padmanee
Wang, Jing
Wargo, Jennifer
Pe'er, Dana
Allison, James
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[28] Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Wei, Spencer C.
Levine, Jacob H.
Cogdill, Alexandria P.
Zhao, Yang
Anang, Nana-Ama A. S.
Andrews, Miles C.
Sharma, Padmanee
Wang, Jing
Wargo, Jennifer A.
Pe'er, Dana
Allison, James P.
CELL, 2017, 170 (06) : 1120 - 1133
[29] Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Patel, Sandip P.
Cano-Linson, Eleanor
Chae, Young Kwang
Schokrpur, Shiruyeh
Lao, Christopher D.
Powers, Benjamin C.
Victor, Adrienne I.
Onitilo, Adedayo A.
Shin, Sarah
Takebe, Naoko
Threlkel, Sara
Mcleod, Christine M.
Chen, Helen X.
Sharon, Elad
Othus, Megan
Ryan, Christopher W.
Blanke, Charles D.
Kurzrock, Razelle
NPJ PRECISION ONCOLOGY, 2025, 9 (01)
[30] Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
Hao, Chunyan
Tian, Jinhui
Liu, Huiling
Li, Fei
Niu, Hongxia
Zhu, Bingdong
MEDICINE, 2017, 96 (26)

← 1 2 3 4 5 →